Hattie Hanley

My tweats are my own.

[Hattie Hanley @HattieHanley]

ASCVD stage 1-4 will PREVENT Stroke & MI ♥️Thank Doctors Budoff, Anthony Demaria (UCSD) DJ Maron (Stanford) Wm. Bommer (UCDavis) Sarah Epstein (UCBerkeley) Eveline Stock (UCSF) Allen Taylor (Georgetown-Medstar) ND Wong (UCIrvine) Dane Fisher & Joe Sky (AF Cardiology & Radiology)!

[Eric Topol @EricTopol]

The pace of walking is another important factor of exercise w/r to a link with cardiovascular and all-cause mortality
Summary of findings from @uk_biobank large cohort study https://t.co/ljTTE0oWRJ

[Eric Topol @EricTopol]

This is a big bust, folks
The first large scale (N>8000 participants) for lowering Lp(a) did not meet its primary endpoint for reducing adverse cardiovascular outcomes (vs placebo) https://t.co/dNV6RHXtJb

[Ron Blankstein @RonBlankstein]

For today's @BrighamWomens @BWHCVImaging Grand Rounds, we have our very own prevention & imaging star @RCardoso_MD talking about #CAC testing --> direct measurement of plaque ; robust risk discrimination ; amount of CAC can help determine type & intensity of Rx!🎯

[SABOURETCardiologist @SABOURETCardio]

These data reinforce our editorial advocating a systematic report of #CAC for every chest #CTscan

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

#SouthAsian #CAC #risk
@ourhealthstudy @IndiasporaForum

Such important data for us to know.

Thank you for this critical work.

[JACC Journals @JACCJournals]

In a new study from #MESA, #CAC distribution (number & specific arteries) was assoc w/ risk & improved risk prediction independent of traditional risk factors & plaque burden assessed by CAC volume & density. https://t.co/vmZiKGRmS0 #JACCIMG @hsbhatia @TaraAllenMD

[Khurram Nasir @khurramn1]

In the midst of so much hypes around us, probably a very correct & balanced description for #CAC & #PowerOfZero 👇

⁦@MichaelJBlaha⁩ ⁦@RonBlankstein⁩ ⁦@rblument1⁩

This Test Can See a Heart Attack in Your Future - The New York Times https://t.co/0CU72fpJDW

[Eric Topol @EricTopol]

Do blood thinners prevent stroke and embolism safely (without major bleeding) in people with atrial fibrillation and only 1 risk factor?
There hadn't been a randomized trial. Until today #ESCCongress @NEJM
The answer is yes. ~ 70% relative reduction, small 1% absolute reduction
https://t.co/h5rjj4RpaN

[Eric Topol @EricTopol]

Silent atherosclerosis can start early in life and follows patterns by age and sex throughout the lifespan, from a large cohort of >16,000 participants age 18-70 years #ESCCongress @NEJM
https://t.co/nxGNykGgst

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

🫀 #STAREE at #ESCCongress

Do statins benefit healthy adults ≥70 years? Yes!

Atorvastatin 40 mg vs placebo, ~6 years.

❤️ Major CV events: 10.9 vs 15.5/1,000 person-years
HR 0.70 (95% CI 0.61–0.82) ✅

🧠 Disability-free survival (death, dementia or persistent disability): 21.6 vs 23.0/1,000 person-years
HR 0.94 (0.84–1.05) ❌

Takeaway: In older adults without established CVD, statin therapy produced a substantial 30% relative reduction in major CV events, but did not significantly prolong disability-free survival.

📄 @NEJM
https://t.co/L7G1zbMGfQ

#Statins #Prevention #CardioTwitter

[Eric Topol @EricTopol]

“Every cell in your body contains a memory of its youth. Now a fiercely contested, billionaire-backed race is quietly underway to reawaken those memories. Doctors think this cellular reprogramming—just entering its first human trials—could wipe out dozens of ailments. Longevity experts are harnessing it for something even grander."

Status (reality) report: There is only one ongoing clinical trial in 12-18 patients with optic nerve conditions who will receive 3 transcription "Yamanaka" factors directly injected in their eye https://t.co/MiIhNpRsz5

[Khurram Nasir @khurramn1]

Just read advocacy for OTC statins

Seems like many pt denied the statin they deserve.. and suddenly they will be grateful that it is so widely available

In fact hardest part is convincing majority to even consider statins

Just feel folks are divorced from ground reality

@rblument1 @MichaelJBlaha

[Matthew Budoff MD @BudoffMd]

Just received word from NIH that we will be funded to look at @bdi_ai analytics of liver fat, epicardial fat and PFAI in 900 participants of the MASALA Study.

[Pope Leo XIV @Pontifex]

Let us #PrayTogether for a just and sustainable management of water, a vital resource, so that everyone may have equal access to it. #PrayerIntention @clicktopray_en @vaticanIHD https://t.co/rCmSKkqM3b

[RonaldReaganLibrary @Reagan_Library]

September 1st is World Letter Writing Day!

Part of the Reagan Library’s collection consists of letters from around the world. See some of these letters and more in a new interactive website, “Letters to the President.”

Click the link to explore: https://t.co/9GGoMSjDKG

[Axel Diederichsen @ADiederichsen]

Vitamin K2 in future treatment of coronary atherosclerosis?
We will know in two years!
Thanks to a brilliant team!

[Axel Diederichsen @ADiederichsen]

Is DANCAVAS really the most important screening study of the last 50 years?
That is the question posed by authors in a commentary in the American Journal of Preventive Cardiology: https://t.co/JtZRhsHmmJ
@BudoffMd @MichaelJBlaha

[Axel Diederichsen @ADiederichsen]

DANCAVAS: Does a cardiovascular screening examination including a CT scan reduce all-cause mortality?
This was the case among men aged 65 to 69 years — but what about men aged 60 to 64?
The results will be presented at the #ESCCongress 2025.

[Axel Diederichsen @ADiederichsen]

CAC increased by 196 AU with vitamin K2 + D3 vs 248 AU with placebo.

Between-group difference: −52 AU (95% CI −79 to −24).

The effect was consistent across sex and baseline CAC subgroups.

[Axel Diederichsen @ADiederichsen]

Can vitamin K2 + D3 slow severe coronary calcification?

In DANCODE (n=398, CAC ≥400), CAC progression was 21% lower with vitamin K2 + D3 vs placebo over 24 months.

Presented at #ESCCongress and published in Circulation.
Read the article⁠: https://t.co/W1pTmewXKj